Form 8-K - Current report:
SEC Accession No. 0001140361-25-018795
Filing Date
2025-05-14
Accepted
2025-05-14 07:10:19
Documents
15
Period of Report
2025-05-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20048841_8k.htm   iXBRL 8-K 30394
2 EXHIBIT 99.1 ef20048841_ex99-1.htm EX-99.1 133254
6 image00001.jpg GRAPHIC 2828
  Complete submission text file 0001140361-25-018795.txt   319524

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA atai-20250514.xsd EX-101.SCH 3973
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE atai-20250514_lab.xml EX-101.LAB 22690
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atai-20250514_pre.xml EX-101.PRE 16546
18 EXTRACTED XBRL INSTANCE DOCUMENT ef20048841_8k_htm.xml XML 4213
Mailing Address WALLSTRASSE 16 BERLIN 2M 10179
Business Address WALLSTRASSE 16 BERLIN 2M 10179 49 89 2153 9035
ATAI Life Sciences N.V. (Filer) CIK: 0001840904 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40493 | Film No.: 25942621
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)